Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pacritinib in Patients With Myelofibrosis

Pacritinib in Patients With Myelofibrosis Letters Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland Corresponding Author: Henry H. Lindner, MD, Hormone Restoration, (Prasad); Department of Public Health and Preventive Medicine, Oregon Health 230 W Tioga St, Ste 5, Tunkhannock, PA 18657 (hlindner1@yahoo.com). & Science University, Portland (Prasad); Center for Health Care Ethics, Oregon Published Online: October 18, 2018. doi:10.1001/jamaoncol.2018.4637 Health & Science University, Portland (Prasad); Division of General Internal Conflict of Interest Disclosures: None reported. Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania (Gellad). Editorial Note: This letter was shown to the corresponding author of the Corresponding Author: Inmaculada Hernandez, PharmD, PhD, Department of original article, who declined to reply on behalf of the authors. Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, 3501 Terrace St, 637 Salk Hall, Pittsburgh, PA 15261 (inh3@pitt.edu). 1. Kotsopoulos J, Gronwald J, Karlan BY, et al; Hereditary Breast Cancer Clinical Study Group. Hormone replacement therapy after oophorectomy and breast Published Online: October 11, 2018. doi:10.1001/jamaoncol.2018.4657 cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018;4(8):1059-1065. Conflict of Interest Disclosures: Dr Hernandez is funded by the National Heart, doi:10.1001/jamaoncol.2018.0211 Lung, and Blood Institute (grant number K01HL142847). Dr Prasad reports 2. Carroll JS, Hickey TE, Tarulli GA, Williams M, Tilley http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Pacritinib in Patients With Myelofibrosis

Suzuki, Shotaro; Tsuda, Kenji; Tanimoto, Tetsuya
JAMA Oncology , Volume 4 (12) – Dec 25, 2018
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/pacritinib-in-patients-with-myelofibrosis-VXmbx3kNBf

References (4)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2018.4830
Publisher site
See Article on Publisher Site

Abstract

Letters Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland Corresponding Author: Henry H. Lindner, MD, Hormone Restoration, (Prasad); Department of Public Health and Preventive Medicine, Oregon Health 230 W Tioga St, Ste 5, Tunkhannock, PA 18657 (hlindner1@yahoo.com). & Science University, Portland (Prasad); Center for Health Care Ethics, Oregon Published Online: October 18, 2018. doi:10.1001/jamaoncol.2018.4637 Health & Science University, Portland (Prasad); Division of General Internal Conflict of Interest Disclosures: None reported. Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania (Gellad). Editorial Note: This letter was shown to the corresponding author of the Corresponding Author: Inmaculada Hernandez, PharmD, PhD, Department of original article, who declined to reply on behalf of the authors. Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, 3501 Terrace St, 637 Salk Hall, Pittsburgh, PA 15261 (inh3@pitt.edu). 1. Kotsopoulos J, Gronwald J, Karlan BY, et al; Hereditary Breast Cancer Clinical Study Group. Hormone replacement therapy after oophorectomy and breast Published Online: October 11, 2018. doi:10.1001/jamaoncol.2018.4657 cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018;4(8):1059-1065. Conflict of Interest Disclosures: Dr Hernandez is funded by the National Heart, doi:10.1001/jamaoncol.2018.0211 Lung, and Blood Institute (grant number K01HL142847). Dr Prasad reports 2. Carroll JS, Hickey TE, Tarulli GA, Williams M, Tilley

Journal

JAMA Oncology – American Medical Association

Published: Dec 25, 2018

There are no references for this article.